CFI and age-related macular degeneration: In light of the significant morbidity associated with late stage AMD, it would be cost‐effective to measure FI levels in asymptomatic AMD patients (including those with high risk features), and assess whether low FI is a result of pathogenic CFI variants, and amenable to FI supplementation to reduce the risk of progression to GA.